Mahindra & Mahindra

Refer to important disclosures at the end of this report

Commencing the electric UV journey with XUV400

- We attended M&M's EV day, where the company re-iterated its future EV strategies. The recently showcased electric XUV400 model has been developed at an investment of Rs5-6bn. The model features a superior range and acceleration in comparison to peers in the non-luxury segment. Bookings and dispatches are expected to commence in Q4FY23.
- Post XUV400 launch, four more electric models under XUV and BE brands, based on a dedicated platform (INGLO), are scheduled for launch over December 2024 to October 2026. Investments relating to the platform and model development are expected at an aggregate of Rs100bn over FY22-27. M&M will collaborate with Volkswagen for components such as electric drivetrain, battery system, and battery cells.
- We remain positive on M&M due to its sales upcycle across segments and a large order book in PVs (270,000+ units). We have raised our FY23-25E EPS estimates by 3-7%, factoring an increase in volume assumptions.
- We have built in FY22-25E revenue/earnings CAGRs at 23%/21%. We re-affirm Buy with a revised SOTP value of Rs1,490 (Rs1,390 earlier), based on 12x standalone Sep'24E EPS (DCF-based) and the value of subsidiaries/investments at Rs658/share.

Key Takeaways from the Analyst Meet

- M&M has unveiled electric XUV400, with best-in-class acceleration at 8.3 seconds for 0-100km and range of 456km. The model is equipped with connectivity features and multiple drive modes. XUV400, for the most part, looks similar to its ICE-powered sibling (XUV300), but it gets some EV-specific touches. At 4.2meter length, it is longer than XUV300, as EVs do not get any tax benefits for being under four meters. The model has been developed at an investment of Rs5-6bn, which includes cost of platform modification and electrification.
- The announcement of model pricing and order bookings are expected in January 2023. The model is to be launched in a staggered manner, with 16 cities in Phase 1. The model is likely to compete with both B and C segment SUVs (refer Exhibit 1).
- New dedicated EV platform INGLO: The new platform would include the use of blade and prismatic batteries with capacity of 60-80kWH, fast charging up to 175kWH allowing 80% charge in <30 minutes, and output of 170-250kWH to support acceleration of 0-100kmph under six seconds and would allow variable lengths between 4.3-4.8 meters. Vehicles developed off this platform can be obtained with optional all-wheel drive (AWD), multiple drive modes, advanced driver-assistance system (ADAS), and the capability to handle L2+ autonomous driving.

Please see our sector model portfolio (Emkay Alpha Portfolio): Automobiles & Auto Ancillaries (Page 8)

Financial Snapshot (Standalone)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	446,299	574,460	817,413	961,781	1,065,760
EBITDA	69,575	70,423	97,036	117,048	131,022
EBITDA Margin (%)	15.6	12.3	11.9	12.2	12.3
APAT*	35,064	37,809	53,049	68,307	77,591
EPS (Rs)*	28.2	30.4	42.7	54.9	62.4
EPS (% chg)*	37.8	7.8	40.3	28.8	13.6
ROE (%)*	19.0	19.2	22.0	23.2	21.7
P/E (x)*	22.9	21.3	15.2	11.8	10.4
EV/EBITDA (x)*	11.2	10.8	7.6	6.0	4.9
P/BV (x)*	4.6	3.7	3.0	2.5	2.1

Emkay

Your success is our success

СМР	Target Price
Rs 1,297 as of (September 12, 2022)	Rs 1,490 (▲) 12 months
Rating	Upside
BUY (∎)	14.9 %

Change in Estimates

Change in Es	stimat	es		
EPS Chg FY2	23E/F1	/24E (%	6)	3.1/5.6
Target Price of	change	e (%)		7.2
Target Period	(Mon	ths)		12
Previous Rec	0			BUY
Emkay vs Co	onsen	sus		
	EPS E	stimate	es	
		F١	23E	FY24E
Emkay			53.1	65.9
Consensus			53.6	67.3
Mean Conser	isus T	P (12M) F	Rs 1,388
Stock Details	5			
Bloomberg Co	ode			MM IN
Face Value (F	Rs)			5
Shares outsta	Inding	(mn)		1,243
52 Week H/L			1,3	66 / 671
M Cap (Rs br	/USD	bn)	1,612	2 / 20.28
Daily Avg Vol	ume (I	nos.)	4,	142,781
Daily Avg Tur	nover	(US\$ n	ın)	60.7
Shareholding	g Patt	ern Ju	า '22	
Promoters				18.9%
Flls				36.8%
DIIs				28.1%
Public and Ot	hers			16.2%
Price Perform	nance)		
(%)	1M	3M	6M	12M
Absolute	3	25	77	73
Rel. to Nifty	2	13	64	67
Relative pric	e cha	rt		
1325 Rs				80
1190 -			"MA	- 62
1055 -			Kalar	- 44
920 - 🔨	A 4	je	N	- 26
785 -	No alla	W.	•	- 8
650 Sep-21Nov-21	Jan-221	Mar-22Ma	-22 Jul-2	-10 22 Sep-22
	Equity (LHS			Nifty (RHS)

Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Raghunandhan N L

raghunandhan.nl@emkayglobal.com +91 22 6624 2428

Mumuksh Mandlesha

mumuksh.mandlesha@emkayglobal.com +91 22 6612 1334

Bhargava Perni

bhargava.perni@emkayglobal.com +91 22 6624 2429

This report is interface for team.emay genitemarque solution com use and downloaded at 00/10/2022 04.011 m

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Key takeaways from the Analyst Meet (continued)

- M&M will sell EVs under two brands XUV and BE. The first car, XUV.e8 will be launched in India in December 2024, while XUV.e9 will arrive in April 2025. BE.05 will have its market debut in October 2025 and BE.06 will be launched in October 2026 (refer Exhibit 2). Design inputs for these vehicles are being received from India, UK, and Italy centers.
- Led by multiple products, aspirational EV volume target by FY27 stands at 200,000 units, which implies 30% penetration.
- M&M will collaborate with Volkswagen for components for INGLO platform. Volkswagen is expected to supply components such as electric drivetrain, battery system, and battery cells for 1mn+ units over the lifetime of the platform.
- Total investment in the E-PV entity is expected to be Rs100bn, staggered over FY22/23 at Rs20bn, FY24 at Rs20bn, and the remaining Rs60bn over FY25-27. M&M plans to meet a part of the funding over FY24-27 directly or through debt/third-party investors. British International Investment Plc (BII) infusion would be at Rs19.25bn. The Rs100bn investment would cover cost of development of platform and four models.
- On upcoming powertrains, M&M's management has indicated that it will not venture into hybrids and will focus only on EVs.

Exhibit 1: M&M electric XUV400: Scores over B and C segment peers on performance and range

OEM	Model	Ex- showroom price	Battery size	Range (km; ARAI)	Power	Torque	Acceleration (0-100kms)	Length (mm)	Estimated charging time
Mahindra	XUV 400		39.4kW	456		310Nm	8.3	4,200	13 hours (0 to 100%)
Tata	Nexon EV Prime	1,499,000	30.2kW	312	129 PS	245Nm	9.9	3,993	9 hours (10% to 90%)
Tata	Nexon EV Max	1,834,000	40.5kW	437	143PS	250Nm	9.0	3,993	15 hours (10% to 100%)
MG	ZS EV (Exclusive)	2,588,000	50.3kW	461	177PS	280Nm	8.5	4,323	18-19 hours (10% to 100%)
Hyundai	Kona	2,384,000	39.2kW	452	136PS	395Nm	9.7	4,180	19 hours (0 to 100%)

Source: Industry data, Emkay Research

Exhibit 2: Multiple models to be launched on INGLO platform; First four models expected between December 2024 and October 2026



Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 3: Key assumptions; Expect revenue CAGR of 23% over FY22-25E

	FY21	FY22	FY23E	FY24E	FY25E	CAGR % (FY22-25E)
Volumes (units)						
Domestic tractors	343,833	337,052	364,016	389,497	416,762	7
YoY %	17.8	(2.0)	8.0	7.0	7.0	
Domestic PVs	157,215	225,895	371,698	427,968	470,650	28
YoY %	(15.9)	43.7	64.5	15.1	10.0	
Domestic CVs	156,159	177,117	251,870	282,298	305,039	20
YoY %	(21.6)	13.4	42.2	12.1	8.1	
Domestic 3Ws	16,897	30,079	49,630	59,556	63,130	28
YoY %	(70.9)	78.0	65.0	20.0	6.0	
Total Domestic	674,104	770,143	1,037,214	1,159,320	1,255,581	18
YoY %	(8.4)	14.2	34.7	11.8	8.3	
Exports	29,015	50,156	53,912	58,571	63,635	8
YoY %	(21.4)	72.9	7.5	8.6	8.6	
Total Sales	703,119	820,299	1,091,126	1,217,891	1,319,216	17
YoY %	(9.1)	16.7	33.0	11.6	8.3	
Realizations (Rs/unit)	634,741	700,305	749,147	789,710	807,874	5
YoY %	9.4	10.3	7.0	5.4	2.3	
Revenue (Rs mn)	446,299	574,460	817,413	961,781	1,065,760	23
YoY %	(0.5)	28.7	42.3	17.7	10.8	

Source: Company, Emkay Research

Exhibit 4: Change in estimates

Rs mn	FY23E				FY24E				FY25E			
K5 IIII	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY
Volume (units)	1,004,728	1,091,126	8.6	33.0	1,118,539	1,217,891	8.9	11.6	1,199,729	1,319,216	10.0	8.3
Revenue	745,671	817,413	9.6	42.3	849,431	961,781	13.2	17.7	930,134	1,065,760	14.6	10.8
EBIDTA	94,387	97,036	2.8	37.8	111,270	117,048	5.2	20.6	123,284	131,022	6.3	11.9
EBIDTA margin (%)	12.7	11.9	(79) bps	(39) bps	13.1	12.2	(93) bps	30 bps	13.3	12.3	(96) bps	12 bps
Core PAT	51,048	53,049	3.9	40.3	63,947	68,307	6.8	28.8	71,753	77,591	8.1	13.6
Adj. PAT	63,996	65,997	3.1	28.3	77,543	81,903	5.6	24.1	86,029	91,867	6.8	12.2
EPS (Rs)	51.5	53.1	3.1	28.3	62.4	65.9	5.6	24.1	69.2	73.9	6.8	12.2

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 5: SOTP valuation at Rs1,490 implies 15% upside

Components (Rs bn)	Basis of Valuation	Sep'24E Implied P/E (x)	Equity value	M&M stake (%)	Pro- rata value	Hold-co discount (%)	Contr. To SOTP	SOTP (Rs/share)	SOTP breakdown (%)
Tractor division	DCF	17	545		545		545	439	30
CV and 3W divisions	DCF	18	278		278		278	223	15
PV-ICE division	DCF	8	204		204		204	164	11
Standalone business		12	1,028		1,028		1,028	827	56
PV-EV division	Valuation at 40% discount to average pre-money valuation OR Valuation at 30% discount to Tata Motors' E-PV valuation	2.6x FY27E EV/S (TTM) discounted to Sep'24E	285		285		285	229	15
Tech Mahindra	TP (Emkay)		1,205	25.5	308	20	246	198	13
M&M Financial Services	TP (Emkay)		259	52.2	135	20	108	87	6
Other Subs/investments	Current m-cap/ investment value						179	144	10
Total							1,846	1,485	100
Total (Rounded off)								1,490	

Source: Company, Emkay Research; Note: Holdco discount calculated based on factors such as management control, size of free float, listed/unlisted, etc.

Exhibit 6: SOTP change (Change **New SOTP** Earlier SOTP Components (Rs/share) (Rs/share) %) Tractor division 439 432 2 CV and 3W divisions 223 170 31 PV - ICE division 164 141 17 PV - EV division 0 229 229 Core business (S/A + E-PV) 972 9 1,056 -0 Tech Mahindra 198 198 M&M Financial Services 87 87 0 Other Subs/investments 9 144 132 Total 1,490 1,390 7

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM

- Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Key Financials (Standalone)

Income Statement

Y/E March (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	446,299	574,460	817,413	961,781	1,065,760
Expenditure	376,724	504,037	720,377	844,733	934,738
EBITDA	69,575	70,423	97,036	117,048	131,022
Depreciation	23,699	24,511	27,651	30,470	33,436
EBIT	45,876	45,912	69,385	86,579	97,585
Other Income	11,995	20,759	19,571	23,311	25,411
Interest expenses	3,963	2,230	2,117	2,123	2,118
РВТ	53,907	64,441	86,838	107,767	120,878
Тах	13,193	13,002	20,841	25,864	29,011
Extraordinary Items	(30,873)	(2,087)	(410)	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	9,842	49,352	65,588	81,903	91,867
Adjusted PAT	40,714	51,439	65,997	81,903	91,867

Balance Sheet

Y/E March (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity share capital	5,974	5,983	5,983	5,983	5,983
Reserves & surplus	343,536	383,627	432,715	494,142	563,042
Net worth	349,510	389,610	438,698	500,125	569,025
Minority Interest	0	0	0	0	0
Loan Funds	83,584	70,490	70,669	70,835	70,394
Net deferred tax liability	14,497	17,008	17,442	17,981	18,585
Total Liabilities	447,590	477,108	526,809	588,941	658,005
Net block	120,113	145,486	211,809	236,081	253,592
Investment	217,826	251,098	286,098	316,098	361,098
Current Assets	216,451	224,537	293,915	352,675	396,463
Cash & bank balance	63,952	36,505	25,606	36,979	46,636
Other Current Assets	26,570	36,016	51,249	60,300	66,819
Current liabilities & Provision	168,055	194,195	275,962	326,862	363,149
Net current assets	48,397	30,342	17,954	25,814	33,315
Misc. exp	0	0	0	0	0
Total Assets	447,590	477,108	526,809	588,941	658,005

Cash Flow					
Y/E March (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
PBT (Ex-Other income) (NI+Dep)	41,913	43,682	67,268	84,456	95,467
Other Non-Cash items	0	0	0	0	0
Chg in working cap	35,866	4,967	(4,616)	(2,219)	(1,382)
Operating Cashflow	83,942	50,178	75,029	91,259	102,281
Capital expenditure	(33,113)	(31,859)	(54,741)	(54,741)	(50,000)
Free Cash Flow	50,829	18,319	20,289	36,518	52,281
Investments	(120,585)	(29,019)	(35,000)	(30,000)	(45,000)
Other Investing Cash Flow	8,338	17,289	0	0	0
Investing Cashflow	(133,365)	(22,830)	(70,170)	(61,430)	(69,589)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	42,115	(13,168)	179	166	(440)
Dividend paid (incl tax)	(2,936)	(10,891)	(16,499)	(20,476)	(22,967)
Other Financing Cash Flow	35,869	(25,943)	2,679	3,976	2,491
Financing Cashflow	71,010	(54,795)	(15,759)	(18,456)	(23,034)
Net chg in cash	21,587	(27,447)	(10,899)	11,373	9,658
Opening cash position	42,365	63,952	36,505	25,606	36,979
Closing cash position	63,952	36,505	25,606	36,979	46,636

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM

Embray Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Profitability (%)	FY21	FY22	FY23E	FY24E	FY25E
EBITDA Margin	15.6	12.3	11.9	12.2	12.3
EBIT Margin	10.3	8.0	8.5	9.0	9.2
Effective Tax Rate	24.5	20.2	24.0	24.0	24.0
Net Margin	9.1	9.0	8.1	8.5	8.6
ROCE	10.3	10.8	13.3	14.8	14.8
ROE	11.7	13.9	15.9	17.4	17.2
RolC	29.8	30.1	30.7	30.7	31.9
Per Share Data (Rs)	FY21	FY22	FY23E	FY24E	FY25E
EPS	32.7	41.4	53.1	65.9	73.9
CEPS	51.8	61.1	75.3	90.4	100.8
BVPS	281.1	313.4	352.9	402.3	457.7
DPS	8.4	11.1	13.3	16.5	18.5
Valuations (x)	FY21	FY22	FY23E	FY24E	FY25E
PER	39.6	31.3	24.4	19.7	17.6
P/CEPS	25.0	21.2	17.2	14.3	12.9
P/BV	4.6	4.1	3.7	3.2	2.8
EV / Sales	3.6	2.7	1.9	1.6	1.4
EV / EBITDA	22.8	22.3	15.9	12.9	11.1
Dividend Yield (%)	0.6	0.9	1.0	1.3	1.4
	51/04	51/00	51/005	51/045	
Gearing Ratio (x)	FY21	FY22	FY23E	FY24E	FY25E
Net Debt/ Equity	(0.1)	(0.1)	(0.2)	(0.2)	(0.3
Net Debt/EBIDTA	(0.4)	(0.6)	(0.7)	(0.9)	(1.2
Working Cap Cycle (days)	(12.7)	(3.9)	(3.4)	(4.2)	(4.6
Growth (%)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	(0.5)	28.7	42.3	17.7	10.8
EBITDA	9.6	1.2	37.8	20.6	11.9
EBIT	15.0	0.1	51.1	24.8	12.7
PAT	33.0	401.5	32.9	24.9	12.2
Quarterly (Rs mn)	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23
Revenue	117,648	133,054	152,428	171,240	196,126
EBITDA	16,315	16,598	18,048	19,455	23,410
EBITDA Margin (%)	13.9	12.5	11.8	11.4	11.9
PAT	9,351	16,867	13,532	11,672	14,71 <i>°</i>
EPS (Rs)	7.5	13.6	10.9	9.4	11.8
Source: Company, Emkay Research					
Shareholding Pattern (%)	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22
Promoters	18.9	18.9	18.9	18.9	18.9
FIIs	38.9	37.8	37.5	36.2	36.8
DIIs	25.4	26.3	27.0	27.9	28.1

Source: Capitaline

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
05-Aug-22	1,236	1,390	12m	Buy	Raghunandhan NL
10-Jul-22	1,134	1,390	12m	Buy	Raghunandhan NL
28-Jun-22	1,112	1,250	12m	Buy	Raghunandhan NL
30-May-22	998	1,150	12m	Buy	Raghunandhan NL
11-May-22	887	1,070	12m	Buy	Raghunandhan NL
06-Apr-22	828	1,010	12m	Buy	Raghunandhan NL
24-Feb-22	796	1,075	12m	Buy	Raghunandhan NL
10-Feb-22	853	1,075	12m	Buy	Raghunandhan NL
09-Nov-21	892	1,055	12m	Buy	Raghunandhan NL
07-Aug-21	758	920	12m	Buy	Raghunandhan NL
02-Jul-21	783	920	12m	Hold	Raghunandhan NL
18-Jun-21	782	920	12m	Hold	Raghunandhan NL
01-Jun-21	806	920	12m	Hold	Raghunandhan NL
30-May-21	846	920	12m	Hold	Raghunandhan NL
28-May-21	846	920	12m	Hold	Raghunandhan NL
07-Feb-21	866	1,020	12m	Buy	Raghunandhan NL
02-Jan-21	732	824	12m	Buy	Raghunandhan NL
11-Nov-20	633	783	12m	Buy	Raghunandhan NL
11-Oct-20	633	718	12m	Buy	Raghunandhan NL
28-Sep-20	615	718	12m	Buy	Raghunandhan NL
28-Aug-20	631	718	12m	Buy	Raghunandhan NL
07-Aug-20	600	718	12m	Buy	Raghunandhan NL
29-Jun-20	507	572	12m	Buy	Raghunandhan NL
14-Jun-20	508	572	12m	Buy	Raghunandhan NL
15-May-20	381	490	12m	Buy	Raghunandhan NL
04-May-20	357	490	12m	Buy	Raghunandhan NL
13-Apr-20	363	490	12m	Buy	Raghunandhan NL
27-Feb-20	494	697	12m	Buy	Raghunandhan NL
11-Feb-20	524	697	12m	Buy	Raghunandhan NL
09-Feb-20	569	705	12m	Buy	Raghunandhan NL
30-Jan-20	568	705	12m	Buy	Raghunandhan NL
27-Dec-19	530	705	12m	Buy	Raghunandhan NL
27-Nov-19	540	705	12m	Buy	Raghunandhan NL
09-Nov-19	580	705	12m	Buy	Raghunandhan NL
01-Nov-19	590	690	12m	Buy	Raghunandhan NL
30-Oct-19	617	690	12m	Buy	Raghunandhan NL
23-Oct-19	592	690	12m	Buy	Raghunandhan NL
01-Oct-19	557	660	12m	Buy	Raghunandhan NL
26-Sep-19	567	660	12m	Buy	Raghunandhan NL
23-Sep-19	565	660	12m	Buy	Raghunandhan NL

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Emkay Alpha Portfolio – Automobiles & Auto Ancillaries

EAP sector portfolio



Analyst: Raghunandhan NL

Contact Details

raghunandhan.nl@emkayglobal.com +91 22 6624 2428

Sector

Automobiles and Ancillaries

Analyst bio

Raghu holds an MBA and comes with total 13 years of research experience. His team currently covers 17 stocks in the Indian Automobiles and Ancillaries space.

This report is intended for team.emkay@

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	Current NAV	Change vs last published EAP (bps)
Auto & Auto Ancillaries	5.03	5.03	0%	0	100.00	
Amara Raja Batteries	0.00	0.00	NA	0	0.00	0
Apollo Tyres	0.00	0.00	NA	0	0.00	0
Ashok Leyland	0.23	0.26	14%	3	5.09	0
Atul Auto	0.00	0.03	NA	3	0.63	0
Bajaj Auto	0.47	0.34	-29%	-13	6.68	0
Bharat Forge	0.19	0.11	-43%	-8	2.15	0
Eicher Motors	0.46	0.46	0%	0	9.05	0
Escorts	0.00	0.03	NA	3	0.65	0
Exide Industries	0.00	0.00	NA	0	0.00	0
Hero MotoCorp	0.35	0.38	8%	3	7.46	0
Mahindra & Mahindra	1.17	1.20	3%	3	23.85	0
Maruti Suzuki India	1.12	1.15	3%	3	22.82	0
Minda Industries*	0.00	0.00	NA	0	0.00	0
Motherson Sumi Wiring India	0.00	0.00	NA	0	0.00	0
Samvardhana Motherson International	0.00	0.00	NA	0	0.00	0
Tata Motors	0.74	0.75	1%	1	14.86	0
Tata Motors DVR*	0.10	0.12	23%	2	2.38	0
TVS Motor	0.22	0.22	0%	0	4.39	0
Cash	0.00	0.00	NA	0	0.0	0

Source: Emkay Research

High Conviction/Strong Over Weight


Sector portfolio NAV

	Base					Latest
	1-Apr-19	8-Sep-21	10-Mar-22	9-Jun-22	8-Aug-22	9-Sep-22
EAP - Auto & Auto Ancillaries	100.0	118.9	119.6	138.6	156.0	159.3
BSE200 Neutral Weighted Portfolio (ETF)	100.0	118.3	118.7	138.2	155.7	158.7

*Performance measurement base date 1st April 2019 Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - Auto & Auto Ancillaries	2.2%	15.0%	33.3%	34.0%
BSE200 Neutral Weighted Portfolio (ETF)	1.9%	14.9%	33.7%	34.1%
Source: Emkay Research				



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals" Nortfolios Report and is updated on regular intervals

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Emkay Rating Distribution

Completed Date: 13 Sep 2022 02:08:06 (SGT) Dissemination Date: 13 Sep 2022 02:09:06 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of September 12, 2022
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of September 12, 2022.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the September 12, 2022
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services form securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the September 12, 2022

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM

RESTRICTIONS ON I			
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.		
Australia	This report is not for distribution into Australia.		
Hong Kong	This report is not for distribution into Hong Kong.		
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.		
Malaysia	This report is not for distribution into Malaysia.		
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.		
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.		
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.		
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.		
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.		
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.		
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.		

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 09/13/2022 04:07 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.